Table 4—

Incidence of adverse events (AE)

TOBIColistin
Patients n5362
Patients with ≥1 treatment-emergent AE#34 (64.2)31 (50.0)
Respiratory system AE
 Total#26 (49.1)22 (35.5)
 Cough-increased#5 (9.4)11 (17.7)
 Sputum-increased#6 (11.3)8 (12.9)
 Dyspnoea#5 (9.4)7 (11.3)
 Pharyngitis#7 (13.2)3 (4.8)
Patients with ≥1 serious AE#8 (15.1)7 (11.3)
  • Data are presented as n (%)

  • TOBI: tobramycin solution for inhalation

  • #: no significant difference was detected between groups